NFCR affiliated scientists will be well represented at the 113th annual meeting of the American Association for Cancer Research (AACR), which runs from April 8th through April 13th in New Orleans. This event is one of the most important gatherings of cancer scientists in the world. Many of the funded scientists our community has supported will be featured! To celebrate, we will post updates on participating scientists on Twitter. Follow along on social media, tag @NFCR, and use #AACR22 to join the conversation!
Below is a highlight of our participating researchers.
NFCR researcher Yung-Chi Cheng is cited as the senior team member on research being presented in an April 8 session on Preclinical Immunotherapy focused on his lab’s cancer drug candidate, YIV-906, research into which NFCR has funded for decades.
NFCR researcher Ronald DePinho is cited as a senior team member on research being presented in an April 12 session on Tumor Angiogenesis inhibitors.
NFCR researcher Paul Fisher is cited as a senior team member on research being presented in an April 11 session on Genetically Engineered Mouse Models focused on his lab’s studies of mda-9/sdcbp and liver cancer.
NFCR researcher Aaron Hata is cited as a senior team member on research being presented in an April 11 session on Immune Mechanisms Invoked by Other Therapies focused on targeted lung cancer therapies. Hata is also cited as the senior team member on research being presented in an April 11 session on Biomarkers, Models and Mechanisms focused on LKB1 loss and non-small cell lung cancer.
In collaboration with Dr. Hata, Dr. Lin’s research is being presented in an April 10 session on Elucidating Disease Biology and Drug Resistance Mechanism.
NFCR researcher Rakesh Jain is cited as the senior team member on research being presented in an April 8 session on In Vivo Imaging focused on tumor oxygenation during anti-angiogenesis. Also, Jain will deliver an April 10 Meet-the-Expert Session on Improving Treatment of Primary and Metastatic Brain Tumors: Emerging Strategies.
Steven A. Rosenberg, M.D., PhD
At the AACR Annual Meeting, Dr. Rosenberg will be awarded the 2022 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research!
Before this award, Dr. Rosenberg was honored with NFCR’s Szent-Györgyi Prize for Progress for Cancer Research in 2019. Dr. Rosenberg was recognized for his work revolutionizing—if not originating—the field now known as cancer immunotherapy.
Dr. Rosenberg spoke at NFCR’s 2021 Annual Conference, leading a panel discussion titled, ‘Immunotherapy: State of the Art and Future Trends.’ You can watch this panel discussion and the entire conference video on our digital community, the Oncology Metaverse.
Congratulations, Dr. Rosenberg!
Daniel Von Hoff
NFCR researcher Daniel Von Hoff is cited as the senior team member on research being presented in an April 8 session on Phase II Trials in Progress focused on nutritional approaches for pancreatic cancer treatment patients. More of his research will be presented in an April 13 session on Emerging New Anticancer Agents focused on an experimental CDK7 inhibitor in pancreatic cancer models.
In 2021, Dr. Von Hoff was awarded the inaugural AACR Scientific Achievement Award, titled the AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. This award is named in honor of Dr. Von Hoff’s significant contributions to the advancement of cancer research and his leadership in educating the next generations of oncology investigators. NFCR is proud to have provided support in the early stages of Dr. Von Hoff’s impactful career, providing him his first peer-reviewed and approved cancer research funding. The 2022 AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research will be presented on April 10.
NFCR researcher Danny Welch is chairing the April 10 Personalized Career Conversations’ Professional Advancement Session. This session will allow early-career cancer scientists to meet with distinguished cancer researchers.
His work will also be presented in the April 11 session on Breast Cancer Drug Resistance, and Novel Targets focused on triple-negative breast cancer. Welch is considered an expert in this area.
In addition to these appearances, Welch will be a featured Mentor in the April 11 Navigating the Path to a Successful Career in Cancer Research roundtable designed for students, early-career researchers, and early-stage investigators and a featured presenter in the high-profile April 13 integral session, AACR Annual Meeting 2022 Highlights. He will speak on the critical roles of both basic and translational cancer research, two areas core to NFCR’s research approach.
NFCR is committed to supporting leading researchers who pave the way to cures for all types of cancer. If you would like to support projects like these, please make a gift today to help accelerate cancer research.